Alcoholism Psychedelic Therapy: From Bill Wilson to Clinical Trials

Why Is Alcoholism Psychedelic Therapy Getting Serious Attention Again?

The idea behind alcoholism psychedelic therapy is often treated as a recent development, but it is more than seventy years old. What has changed is the quality of the evidence. For decades, the notion that a psychedelic could help someone stop drinking lived on the fringes of medicine, tied to a handful of mid-century experiments and a lot of anecdote. Today, that same idea is being tested with the rigor that any credible treatment requires, and some of the early results are difficult to dismiss.

Alcohol use disorder is one of the most common and most stubborn conditions in medicine. Relapse rates remain high even with the best available care, and many people cycle through treatment repeatedly without lasting change. That reality is part of why researchers and clinicians have returned to a question first raised in the 1950s: can a single, carefully guided psychedelic experience help someone break a pattern that has resisted everything else?

What Did Bill Wilson Actually Believe About LSD and Alcoholism?

Bill Wilson, who co-founded Alcoholics Anonymous in 1935, built the entire twelve-step framework around a single idea: that recovery often begins with a profound shift in perspective, something close to a spiritual awakening. Wilson had experienced exactly that kind of shift himself during a hospital stay, and he came to believe it was central to getting sober and staying sober.

In the late 1950s, Wilson learned about the work of two Canadian psychiatrists, Abram Hoffer and Humphry Osmond, who were giving LSD to alcoholics in Saskatchewan. Their reasoning was that the drug might produce the same illuminating experience that seemed to help some patients finally accept the AA program. According to accounts from the period, patients who might otherwise recover at a rate of around five percent were showing recovery rates closer to fifteen percent after LSD sessions, and at least one study reported figures far higher.

Wilson was skeptical at first. He disliked the idea of giving a mind-altering drug to alcoholics, which on its face seemed to contradict everything AA stood for. But the reported results intrigued him, and he had his first supervised LSD session on August 29, 1956, guided by his friend and spiritual mentor Gerald Heard under the supervision of Dr. Sidney Cohen. Wilson came away convinced that the experience had value, and he even proposed to the AA General Service Board that the organization consider LSD as a tool for recovery.

The board said no. Most members were firmly opposed to their founder experimenting with a psychedelic, and Wilson never publicly urged other members to follow him. He stepped back from active involvement in the experiments, though he continued to believe the approach had merit for some people. When LSD was criminalized in the mid-1960s, research into its therapeutic use stopped almost entirely, and the question sat untouched for nearly half a century.

Was There Any Real Evidence Behind Those Early Claims?

For a long time, the honest answer was that the early results were suggestive but hard to trust. The studies from the 1950s and 1960s varied widely in quality, and enthusiasm often ran ahead of the data. That changed in 2012, when researchers Teri Krebs and Pal-Orjan Johansen went back and analyzed the old trials with modern statistical methods.

They pooled six randomized controlled trials involving 536 participants, all conducted decades earlier. The combined result showed a clear short-term benefit: a single dose of LSD, given alongside an alcoholism treatment program, was associated with reduced alcohol misuse. The effect was statistically significant and consistent across the trials. Notably, the benefit was strongest in the months following treatment and appeared to fade by the one-year mark, which tells us something important about how these treatments likely work best, as a catalyst within a broader program rather than a standalone cure.

This analysis mattered because it took the mid-century claims out of the realm of folklore and gave them a foundation in evidence. It did not prove that psychedelics cure alcoholism. What it showed was that the old researchers were probably onto something real, and that the question deserved a proper modern investigation.

What Does the Modern Research on Alcohol Use Disorder Show?

The most significant modern study came out of New York University in 2022, led by Dr. Michael Bogenschutz and published in JAMA Psychiatry. It was a double-blind randomized controlled trial, the gold standard for testing whether a treatment actually works, involving 93 adults with alcohol use disorder.

All participants received the same course of psychotherapy over twelve weeks. Half were given two doses of psilocybin during that period, and half received an active placebo (an antihistamine chosen because it produces noticeable effects without being psychedelic). Over the eight months of follow-up, the psilocybin group showed a significantly lower percentage of heavy drinking days than the placebo group. In practical terms, people who received psilocybin alongside therapy drank heavily far less often than those who received therapy alone.

This built on an earlier proof-of-concept study Bogenschutz and colleagues published in 2015, which found similar reductions in drinking after psilocybin sessions, though that study lacked a placebo group and so could not rule out other explanations. The 2022 trial addressed that gap directly, which is why it carries more weight. A dose of psilocybin used in these trials was in the range of 25mg, roughly equivalent to three to four grams of dried Psilocybe cubensis mushrooms, though the trials used pharmaceutical-grade synthetic psilocybin for precise and consistent dosing.

Research is continuing. A 2025 phase 2 trial in Switzerland tested a single psilocybin dose for relapse prevention, and other groups are comparing psilocybin against ketamine and testing different dosing approaches. The picture is still forming, and not every study has produced consistent results, which is exactly what we would expect from a field this young.

How Might a Psychedelic Actually Help Someone Stop Drinking?

The honest answer is that researchers are still working this out, but a few mechanisms appear to matter. Psilocybin converts in the body to psilocin, which activates serotonin receptors in the parts of the brain most involved in mood, self-reflection, and habit. What follows is a temporary window in which the brain becomes unusually flexible, more capable of forming new connections and loosening entrenched patterns. Scientists call this neuroplasticity, and it may be part of why a single experience can shift behavior that has resisted years of effort.

There is also the psychological dimension that Bill Wilson intuited decades ago. Many people who recover describe the psychedelic session as producing a shift in how they see themselves and their drinking, a sense of clarity or emotional release that makes change feel possible. This is why the therapy matters as much as the medicine. In every credible trial, the psychedelic is paired with structured preparation and integration, not given in isolation.

What Are the Real Limits and Risks?

This is not a miracle cure, and anyone who frames it that way is misleading you. The evidence, while promising, comes from a small number of trials with modest participant numbers. Not everyone responds, and the benefits documented in the older studies tended to fade over time without ongoing support.

There are also real safety considerations. Psychedelics can be psychologically intense and are not appropriate for people with certain conditions, including a personal or family history of psychosis. Alcohol use disorder frequently occurs alongside other mental health conditions, which makes careful screening essential. These substances remain federally illegal in most of the United States outside of specific regulated settings in Oregon and Colorado, and unsupervised use carries genuine risk. For a fuller picture of who should approach this work with caution, our guide to psychedelic therapy safety and contraindications covers the medical considerations in detail.

What the research supports is measured optimism. Psychedelic-assisted therapy for alcohol use disorder appears to help a meaningful number of people when delivered with proper screening, professional guidance, and integration. It is not a replacement for established treatment, and it works best as one carefully supported part of a larger recovery process.